In this regard, a pilot study was conducted (NCT02975687) to assess the safety and feasibility of CAR-Ts that target a different CD19 epitope, rather than that recognized by FMC63, in pediatric and adult R/R B-ALL patients (34). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.